Prospective	B-study_type
target	O
assessment	O
and	O
multimodal	O
prediction	O
of	O
survival	O
for	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
in	O
multiple	O
myeloma	O
in	O
the	O
GMMG	O
-	O
MM5	O
multicenter	B-study_type
trial	I-study_type
Prospective	B-study_type
target	O
assessment	O
and	O
multimodal	O
prediction	O
of	O
survival	O
for	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
in	O
multiple	O
myeloma	O
in	O
the	O
GMMG	O
-	O
MM5	O
multicenter	B-study_type
trial	I-study_type
DirkHose	B-authors

Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
SusanneBeck	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
HansSalwender	B-authors

Department	O
of	O
Internal	O
Medicine	O
II	O
,	O
Asklepios	O
Klinik	O
Altona	O
Hamburg	O
Germany	O
MartinaEmde	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
UtaBertsch	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
ChristinaKunz	B-authors

Deutsches	O
Krebsforschungszentrum	O
,	O
Abteilung	O
für	O
Biostatistik	O
Heidelberg	O
Germany	O
MarcSRaab	B-authors
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
HartmutGoldschmidt	B-authors
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O

Department	O
of	O
Biological	O
Hematology	O
,	O
CHU	O
Montpellier	O
Montpellier	O
France	O
AnjaSeckinger	B-authors
anja.seckinger@med.uni-heidelberg.de	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O

Prospective	B-study_type
target	O
assessment	O
and	O
multimodal	O
prediction	O
of	O
survival	O
for	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
in	O
multiple	O
myeloma	O
in	O
the	O
GMMG	O
-	O
MM5	O
multicenter	B-study_type
trial	I-study_type

Received	O
:	O
29	O
March	O
2019	O
Accepted	O
:	O
12	O
June	O
2019	O
DirkHose	B-authors
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
SusanneBeck	B-authors
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
HansSalwender	B-authors

Department	O
of	O
Internal	O
Medicine	O
II	O
,	O
Asklepios	O
Klinik	O
Altona	O
Hamburg	O
Germany	O
MartinaEmde	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
UtaBertsch	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
ChristinaKunz	B-authors

Deutsches	O
Krebsforschungszentrum	O
,	O
Abteilung	O
für	O
Biostatistik	O
Heidelberg	O
Germany	O
MarcSRaab	B-authors
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
HartmutGoldschmidt	B-authors
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O

Department	O
of	O
Biological	O
Hematology	O
,	O
CHU	O
Montpellier	O
Montpellier	O
France	O
AnjaSeckinger	B-authors
anja.seckinger@med.uni-heidelberg.de	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O

Prospective	B-study_type
target	O
assessment	O
and	O
multimodal	O
prediction	O
of	O
survival	O
for	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
in	O
multiple	O
myeloma	O
in	O
the	O
GMMG	O
-	O
MM5	O
multicenter	B-study_type
trial	I-study_type

Received	O
:	O
29	O
March	O
2019	O
Accepted	O
:	O
12	O
June	O
2019	O
DirkHose	B-authors
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
SusanneBeck	B-authors
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
HansSalwender	B-authors

Department	O
of	O
Internal	O
Medicine	O
II	O
,	O
Asklepios	O
Klinik	O
Altona	O
Hamburg	O
Germany	O
MartinaEmde	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
UtaBertsch	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
ChristinaKunz	B-authors

Deutsches	O
Krebsforschungszentrum	O
,	O
Abteilung	O
für	O
Biostatistik	O
Heidelberg	O
Germany	O
MarcSRaab	B-authors
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
HartmutGoldschmidt	B-authors
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O

Department	O
of	O
Biological	O
Hematology	O
,	O
CHU	O
Montpellier	O
Montpellier	O
France	O
AnjaSeckinger	B-authors
anja.seckinger@med.uni-heidelberg.de	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O

Prospective	B-study_type
target	O
assessment	O
and	O
multimodal	O
prediction	O
of	O
survival	O
for	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
in	O
multiple	O
myeloma	O
in	O
the	O
GMMG	O
-	O
MM5	O
multicenter	B-study_type
trial	I-study_type
DirkHose	B-authors
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O

Germany	O
Heidelberg	O
Germany	O
SusanneBeck	B-authors
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O

Germany	O
Hamburg	O
Germany	O
MartinaEmde	B-authors
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O

France	O
Montpellier	O
France	O
AnjaSeckinger	B-authors
anja.seckinger@med.uni-heidelberg.de	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O

Germany	O
Heidelberg	O
Germany	O
Prospective	B-study_type
target	O
assessment	O
and	O
multimodal	O
prediction	O
of	O
survival	O
for	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
in	O
multiple	O
myeloma	O
in	O
the	O
GMMG	O
-	O
MM5	O
multicenter	B-study_type
trial	I-study_type
10.1186	O
/	O
s13045	O
-	O
019	O
-	O
0750	O
-	O
5	O
Received	O
:	O
29	O
March	O
2019	O
Accepted	O
:	O
12	O
June	O
2019	O

Multiple	O
myeloma	O
is	O
a	O
malignant	O
hematological	O
disease	O
characterized	O
by	O
accumulation	O
of	O
clonal	O
plasma	O
cells	O
in	O
the	O
bone	O
marrow	O
and	O
associated	O
clinical	O
signs	O
and	O
symptoms	O
,	O
especially	O
those	O
related	O
to	O
the	O
displacement	O
of	O
normal	O
hematopoiesis	O
and	O
generation	O
of	O
osteolytic	O
bone	O
disease	O
[	O
1	O
]	O
.	O

Introduction	O
of	O
high	O
-	O
dose	O
melphalan	O
followed	O
by	O
autologous	O
stem	O
cell	O
transplantation	O
,	O
proteasome	O
inhibitors	O
,	O
immunomodulatory	O
drugs	O
,	O
and	O
monoclonal	O
antibodies	O
improved	O
survival	O
[	O
2][3][4][5	O
]	O
without	O
curing	O
a	O
significant	O
fraction	O
of	O
patients	O
.	O
Prognosis	O
of	O
individual	O
patients	O
is	O
highly	O
heterogeneous	O
:	O
current	O
treatment	O
algorithms	O
do	O
well	O
for	O
some	O
patient	O
groups	O
with	O
a	O
median	O
survival	O
of	O
more	O
than	O
10	O
years	O
,	O
while	O
a	O
significant	O
proportion	O
of	O
patients	O
shows	O
median	O
survival	O
of	O
2	O
years	O
or	O
even	O
below	O
[	O
6,7	O
]	O
.	O
This	O
frequently	O
prompts	O
the	O
suggestion	O
to	O
treat	O
the	O
latter	O
patients	O
differently	O
,	O
most	O
often	O
more	O
aggressively	O
,	O
in	O
other	O
terms	O
to	O
perform	O
risk	O
-	O
adapted	O
treatment	O
,	O
e.g.	O
,	O
UAMS	O
total	O
therapy	O
[	O
8	O
]	O
,	O
mSMART	O
by	O
the	O
Mayo	O
Clinic	O
[	O
9	O
]	O
,	O
or	O
the	O
GMMG	O
-	O
CONCEPT	O
trial	O
(	O
NCT03104842	O
)	O
.	O

Risk	O
stratifications	O
in	O
clinical	O
routine	O
are	O
usually	O
performed	O
by	O
combination	O
of	O
presence	O
of	O
high	O
-	O
risk	O
chromosomal	O
aberrations	O
as	O
detected	O
by	O
interphase	O
fluorescence	O
in	O
-	O
situ	O
hybridization	O
(	O
iFISH	O
)	O
and	O
the	O
International	O
Staging	O
System	O
(	O
ISS	O
)	O
as	O
exemplified	O
by	O
the	O
revised	O
ISS	O
score	O
(	O
rISS	O
)	O
and	O
others	O
[	O
10][11][12	O
]	O
.	O
At	O
the	O
same	O
time	O
,	O
prognostic	O
power	O
can	O
be	O
increased	O
by	O
assessing	O
gene	O
expression	O
,	O
i.e.	O
,	O
proliferation	O
[	O
13	O
]	O
and	O
high	O
risk	O
scores	O
[	O
14][15][16][17][18][19][20	O
]	O
,	O
e.g.	O
,	O
by	O
DNAmicroarrays	O
(	O
gene	O
expression	O
profiling	O
,	O
GEP	O
)	O
.	O
This	O
is	O
,	O
however	O
,	O
rarely	O
used	O
prospectively	O
in	O
clinical	O
routine	O
or	O
in	O
a	O
clinical	O
trial	O
setting	O
.	O
In	O
turn	O
,	O
ending	O
up	O
with	O
a	O
variety	O
of	O
clinical	O
and	O
molecular	O
prognostic	O
factors	O
,	O
it	O
is	O
necessary	O
to	O
integrate	O
different	O
factors	O
into	O
a	O
single	O
prognostic	O
information	O
(	O
metascoring	O
)	O
.	O

Besides	O
risk	O
stratification	O
,	O
assessment	O
of	O
gene	O
expression	O
allows	O
investigation	O
of	O
aberrantly	O
or	O
overexpressed	O
targets	O
exemplified	O
by	O
Aurora	O
-	O
kinase	O
A	O
(	O
AURKA	O
)	O
[	O
21	O
]	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptor	O
(	O
IGF1R	O
)	O
[	O
22	O
]	O
.	O
Expression	O
of	O
these	O
targets	O
,	O
in	O
turn	O
,	O
is	O
associated	O
with	O
adverse	O
survival	O
[	O
21,22	O
]	O
.	O
For	O
potential	O
personalized	O
treatment	O
,	O
the	O
addition	O
of	O
clinical	O
grade	O
inhibitors	O
to	O
a	O
backbone	O
treatment	O
only	O
in	O
those	O
patients	O
whose	O
myeloma	O
cells	O
actually	O
express	O
the	O
respective	O
target	O
could	O
be	O
envisioned	O
.	O
Whereas	O
the	O
number	O
of	O
actionable	O
targets	O
in	O
multiple	O
myeloma	O
is	O
currently	O
largely	O
limited	O
,	O
it	O
is	O
very	O
likely	O
that	O
the	O
advent	O
of	O
immunotherapy	O
will	O
change	O
this	O
.	O

Both	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
prerequisite	O
the	O
feasibility	O
of	O
prospective	O
assessment	O
and	O
reporting	O
of	O
targets	O
and	O
prediction	O
of	O
survival	O
probability	O
in	O
clinical	O
routine	O
in	O
a	O
high	O
enough	O
percentage	O
of	O
patients	O
.	O
For	O
phase	O
III	O
trial	O
strategies	O
,	O
e.g.	O
,	O
selecting	O
an	O
add	O
-	O
on	O
treatment	O
,	O
the	O
necessary	O
threshold	O
based	O
on	O
power	O
calculations	O
and	O
clinical	O
feasibility	O
could	O
be	O
estimated	O
as	O
80	O
%	O
of	O
the	O
actual	O
population	O
of	O
patients	O
included	O
in	O
the	O
trial	O
.	O
It	O
is	O
interesting	O
to	O
denote	O
that	O
,	O
despite	O
of	O
course	O
iFISH	O
and	O
GEP	O
have	O
been	O
used	O
in	O
an	O
academic	O
setting	O
or	O
using	O
commercial	O
providers	O
[	O
8,17,[23][24][25][26][27][28	O
]	O
,	O
the	O
question	O
has	O
yet	O
not	O
been	O
answered	O
if	O
this	O
is	O
possible	O
in	O
terms	O
of	O
a	O
prospective	O
molecular	O
analysis	O
and	O
reporting	O
,	O
as	O
opposed	O
to	O
being	O
conducted	O
in	O
a	O
prospective	O
clinical	O
trial	O
.	O
Our	O
study	O
group	O
sees	O
such	O
a	O
proof	O
as	O
prerequisite	O
for	O
indeed	O
planning	O
a	O
clinical	O
trial	O
based	O
on	O
molecular	O
diagnostics	O
such	O
as	O
GEP	O
or	O
RNA	O
-	O
sequencing	O
.	O

Aims	O
of	O
this	O
study	O
were	O
thus	O
:	O
(	O
i	O
)	O
set	O
up	O
a	O
sampling	O
,	O
experimental	O
and	O
analysis	O
strategy	O
to	O
perform	O
iFISH	B-arm_description
in	O
≥	O
90	O
%	O
and	O
GEP	B-arm_description
in	O
≥	O
80	O
%	O
of	O
patients	O
within	O
the	O
first	O
cycle	O
of	O
induction	O
chemotherapy	O
.	O
(	O
ii	O
)	O
Report	O
to	O
patients	O
and	O
physicians	O
within	O
this	O
time	O
to	O
be	O
able	O
to	O
draw	O
a	O
clinical	O
consequence	O
.	O
(	O
iii	O
)	O
Prospectively	O
validate	O
this	O
strategy	O
in	O
the	O
randomized	O
phase	O
III	O
multicenter	O
GMMG	O
-	O
MM5-trial	O
including	O
assessment	O
of	O
potential	O
targets	O
(	O
based	O
on	O
GEP	B-arm_description
)	O
and	O
multimodal	O
assessment	O
of	O
risk	O
using	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
gene	O
expression	O
-	O
based	O
prognostic	O
factors	O
and	O
their	O
integration	O
into	O
a	O
metascore	O
in	O
clinical	O
routine	O
.	O

Sixty	O
to	O
80	O
ml	O
of	O
heparinized	O
bone	O
marrow	O
(	O
i.e.	O
,	O
3	O
-	O
4	O
×	O
18	O
ml	O
of	O
bone	O
marrow	O
plus	O
2	O
ml	O
of	O
heparin	O
per	O
syringe	O
,	O
aspirated	O
with	O
three	O
bone	O
marrow	O
punctures	O
within	O
one	O
anesthetized	O
region	O
)	O
were	O
drawn	O
before	O
the	O
start	O
of	O
chemotherapy	O
and	O
sent	O
to	O
the	O
Multiple	O
Myeloma	O
Research	O
Laboratory	O
Heidelberg	O
by	O
overnight	O
express	O
.	O
For	O
in	O
-	O
house	O
samples	O
,	O
technicians	O
of	O
the	O
Multiple	O
Myeloma	O
Research	O
Laboratory	O
attended	O
the	O
bone	O
marrow	O
aspiration	O
providing	O
assistance	O
to	O
the	O
physician	O
and	O
allowing	O
the	O
fastest	O
possible	O
processing	O
of	O
the	O
samples	O
.	O
Plasma	O
cell	O
purification	O
including	O
quality	O
control	O
and	O
preparation	O
of	O
samples	O
for	O
iFISH	O
(	O
i.e.	O
,	O
cytospins	O
)	O
and	O
GEP	O
(	O
see	O
below	O
for	O
details	O
)	O
were	O
performed	O
centrally	O
according	O
to	O
our	O
laboratory	O
SOP	O
immediately	O
after	O
the	O
arrival	O
of	O
the	O
sample	O
.	O
Sample	O
submitting	O
centers	O
were	O
informed	O
electronically	O
about	O
the	O
quality	O
of	O
the	O
aspirate	O
and	O
the	O
results	O
of	O
the	O
plasma	O
cell	O
purification	O
.	O

Density	O
gradient	O
centrifugation	O
of	O
bone	O
marrow	O
aspirates	O
over	O
Ficoll	O
Hypaque	O
(	O
Biochrom	O
,	O
Berlin	O
,	O
Germany	O
)	O
was	O
performed	O
to	O
separate	O
mononuclear	O
cells	O
by	O
standard	O
protocol	O
.	O
CD138	O
+	O
plasma	O
cells	O
were	O
isolated	O
using	O
anti	O
-	O
CD138	O
immunobeads	O
and	O
an	O
autoMACS	O
Pro	O
Separator	O
(	O
Miltenyi	O
Biotec	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
as	O
published	O
[	O
13,21,[30][31][32][33][34][35	O
]	O
.	O
Purity	O
was	O
assessed	O
by	O
flow	O
cytometry	O
(	O
Becton	O
Dickinson	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
using	O
antibodies	O
against	O
CD38	O
(	O
clone	O
HB-7	O
,	O
FITClabeled	O
;	O
Becton	O
Dickinson	O
)	O
and	O
CD138	O
(	O
clone	O
B	O
-	O
B4	O
,	O
PElabeled	O
;	O
Miltenyi	O
Biotec	O
)	O
.	O
Aliquots	O
of	O
CD138	O
+	O
malignant	O
plasma	O
cells	O
were	O
subjected	O
to	O
cytospin	O
preparation	O
with	O
5000	O
cells	O
per	O
dot	O
for	O
iFISH	B-arm_description
analysis	O
(	O
n	O
=	O
556	O
patients	O
)	O
and	O
RNA	O
/	O
DNA	O
extraction	O
for	O
gene	O
expression	O
profiling	O
(	O
n	O
=	O
458	O
)	O
.	O

Interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
iFISH	B-arm_description
analysis	O
was	O
conducted	O
on	O
CD138-purified	O
plasma	O
cells	O
using	O
probes	O
for	O
numerical	O
changes	O
of	O
the	O
chromosome	O
regions	O
1q21	O
,	O
5p15	O
,	O
5q31	O
or	O
5q35	O
,	O
8p21	O
,	O
9q34	O
,	O
11q22.3	O
or	O
11q23	O
,	O
13q14.3	O
,	O
15q22	O
,	O
17p13	O
,	O
and	O
19q13	O
,	O
as	O
well	O
as	O
translocations	O
t(4;14)(p16.3;q32.3	O
)	O
,	O
t(11;14)(q13	O
;	O
q32.3	O
)	O
,	O
and	O
t(14;16)(q32.3;q23	O
)	O
or	O
any	O
other	O
IgH	O
rearrangement	O
with	O
unknown	O
translocation	O
partner	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Kreatech	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
and	O
MetaSystems	O
,	O
Altlussheim	O
,	O
Germany	O
)	O
and	O
data	O
were	O
analyzed	O
as	O
published	O
[	O
36	O
]	O
.	O

RNA	O
was	O
extracted	O
using	O
the	O
Qiagen	O
AllPrep	O
DNA/	O
RNA	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O
Quality	O
control	O
and	O
quantification	O
of	O
total	O
RNA	O
was	O
performed	O
using	O
an	O
Agilent	O
2100	O
bioanalyzer	O
(	O
Agilent	O
,	O
Frankfurt	O
,	O
Germany	O
)	O
.	O

Gene	O
expression	O
profiling	O
using	O
U133	O
2.0	O
plus	O
arrays	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
was	O
performed	O
as	O
published	O
[	O
13,32,33	O
]	O
.	O
Expression	O
data	O
are	O
deposited	O
in	O
ArrayExpress	O
under	O
accession	O
number	O
E	O
-	O
MTAB-2299	O
.	O

Our	O
gene	O
expression	O
report	O
(	O
GEP	B-arm_description
-	O
R	O
)	O
[	O
31	O
]	O
is	O
a	O
noncommercial	O
software	O
framework	O
developed	O
within	O
the	O
open	O
source	O
software	O
environments	O
R	O
[	O
37	O
]	O
and	O
Bioconductor	O
[	O
38	O
]	O
that	O
can	O
be	O
adapted	O
to	O
other	O
parameters	O
or	O
disease	O
entities	O
.	O
It	O
includes	O
classifications	O
of	O
myeloma	O
,	O
i.e.	O
,	O
TC	O
[	O
39]-	O
,	O
EC	O
[	O
40]-	O
,	O
and	O
molecular	O
classification	O
[	O
41	O
]	O
,	O
risk	O
stratification	O
,	O
i.e.	O
,	O
UAMS	O
GEP70	O
[	O
14]-and	O
IFM	O
15gene	O
score	O
[	O
15	O
]	O
,	O
and	O
our	O
gene	O
expression	O
-	O
based	O
proliferation	O
index	O
(	O
GPI	O
)	O
[	O
13	O
]	O
,	O
and	O
assessment	O
of	O
target	O
gene	O
expression	O
,	O
e.g.	O
,	O
for	O
immunotherapeutic	O
or	O
individualized	O
treatment	O
approaches	O
,	O
into	O
one	O
report	O
.	O
The	O
GEP	B-arm_description
-	O
R	O
runs	O
a	O
quality	O
and	O
identity	O
control	O
;	O
the	O
latter	O
is	O
based	O
on	O
prediction	O
analysis	O
for	O
microarrays	O
(	O
PAM	O
)	O
[	O
42	O
]	O
predictors	O
for	O
sex	O
,	O
IgL	O
(	O
lambda	O
,	O
kappa	O
)	O
,	O
and	O
IgH	O
type	O
(	O
IgA	O
,	O
IgG	O
,	O
IgD	O
)	O
.	O
Results	O
are	O
reported	O
as	O
pdf	O
document	O
consisting	O
of	O
a	O
two	O
pages	O
report	O
given	O
to	O
the	O
treating	O
physician	O
and	O
an	O
appendix	O
containing	O
details	O
regarding	O
the	O
quality	O
and	O
identity	O
control	O
,	O
as	O
well	O
as	O
the	O
assessment	O
of	O
gene	O
expression	O
.	O
Within	O
the	O
GEP	B-arm_description
-	O
R	O
,	O
the	O
implemented	O
HM	O
metascore	O
integrates	O
gene	O
expression	O
-	O
based	O
and	O
conventional	O
prognostic	O
factors	O
into	O
one	O
prognostic	O
classification	O
[	O
31	O
]	O
.	O
The	O
HM	O
metascore	O
has	O
already	O
been	O
validated	O
by	O
crossvalidation	O
and	O
an	O
external	O
validation	O
cohort	O
[	O
31	O
]	O
.	O

Effects	O
were	O
considered	O
statistically	O
significant	O
if	O
the	O
Pvalue	O
of	O
corresponding	O
statistical	O
tests	O
was	O
below	O
5	O
%	O
.	O
Overall	O
(	O
OS	O
)	O
and	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
were	O
investigated	O
using	O
Cox	O
's	O
proportional	O
hazard	O
model	O
as	O
published	O
[	O
43,44	O
]	O
.	O
Survival	O
curves	O
were	O
computed	O
with	O
nonparametric	O
survival	O
estimates	O
for	O
censored	O
data	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
[	O
45,46	O
]	O
.	O
Difference	O
between	O
the	O
curves	O
was	O
tested	O
using	O
the	O
G	O
-	O
rho	O
Log	O
-	O
rank	O
test	O
[	O
47	O
]	O
.	O
A	O
subset	O
of	O
451	O
patients	O
with	O
complete	O
prediction	O
information	O
was	O
used	O
within	O
a	O
73	O
months	O
period	O
for	O
evaluating	O
the	O
performance	O
of	O
the	O
risk	O
prediction	O
models	O
in	O
OS	O
analysis	O
.	O
Cox	O
's	O
proportional	O
hazard	O
models	O
were	O
used	O
as	O
input	O
;	O
for	O
cross	O
-	O
validation	O
,	O
subsampling	O
parameter	O
of	O
301	O
and	O
bootstrapping	O
parameter	O
of	O
150	O
were	O
chosen	O
.	O
The	O
integrated	O
Brier	O
score	O
was	O
used	O
to	O
assess	O
prediction	O
accuracy	O
[	O
48][49][50	O
]	O
.	O
For	O
statistical	O
testing	O
,	O
the	O
van	O
de	O
Wiel	O
test	O
was	O
used	O
[	O
50	O
]	O
.	O

Six	O
hundred	O
and	O
four	O
patients	O
were	O
included	O
in	O
the	O
GMMG	O
multicenter	O
MM5-trial	O
between	O
July	O
2010	O
and	O
November	O
2013	O
,	O
with	O
a	O
total	O
of	O
31	O
participating	O
transplant	O
centers	O
and	O
75	O
associated	O
sites	O
throughout	O
Germany	O
.	O
In	O
accordance	O
with	O
the	O
pre	O
-	O
planned	O
prospective	O
protocol	O
,	O
bone	O
marrow	O
aspirates	O
at	O
the	O
time	O
of	O
inclusion	O
in	O
the	O
study	O
,	O
i.e.	O
,	O
before	O
start	O
of	O
treatment	O
,	O
were	O
available	O
for	O
n	O
=	O
573	O
patients	O
(	O
94.9	O
%	O
)	O
with	O
a	O
median	O
volume	O
of	O
75	O
ml	O
(	O
standard	O
deviation	O
(	O
SD	O
)	O
:	O
23.4	O
)	O
,	O
of	O
whom	O
we	O
were	O
able	O
to	O
successfully	O
perform	O
plasma	O
cell	O
purification	O
followed	O
by	O
quality	O
control	O
using	O
flow	O
cytometry	O
for	O
n	O
=	O
559	O
patients	O
(	O
97.6	O
%	O
)	O
according	O
to	O
our	O
laboratory	O
SOP	O
.	O
The	O
31	O
lacking	O
samples	O
(	O
5.1	O
%	O
)	O
were	O
due	O
to	O
patients	O
declining	O
the	O
bone	O
marrow	O
aspiration	O
(	O
2.5	O
%	O
)	O
or	O
punctio	O
sicca	O
(	O
2.5	O
%	O
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O
Median	O
purity	O
according	O
to	O
CD38/	O
CD138	O
double	O
staining	O
was	O
87.9	O
%	O
(	O
SD	O
16.5	O
%	O
)	O
with	O
a	O
median	O
cell	O
number	O
of	O
1.2	O
×	O
10	O
6	O
cells	O
(	O
SD	O
8.5	O
×	O
10	O
6	O
)	O
.	O

iFISH	B-arm_description
using	O
cytospins	O
from	O
CD138-purified	O
plasma	O
cells	O
was	O
performed	O
centrally	O
for	O
the	O
trial	O
(	O
Multiple	O
Myeloma	O
Research	O
Laboratory	O
and	O
Department	O
of	O
Human	O
Genetics	O
)	O
.	O

Cytospins	O
were	O
prepared	O
with	O
5000	O
cells	O
per	O
dot	O
on	O
the	O
day	O
of	O
purification	O
and	O
hybridized	O
immediately	O
thereafter	O
.	O
Data	O
could	O
be	O
obtained	O
for	O
556/573	O
patients	O
with	O
available	O
bone	O
marrow	O
aspirates	O
(	O
97	O
%	O
)	O
and	O
556/559	O
patients	O
with	O
available	O
CD138-purified	O
plasma	O
cells	O
,	O
respectively	O
(	O
99.5	O
%	O
;	O
Fig	O
.	O
1	O
)	O
.	O
The	O
median	O
proportion	O
of	O
malignant	O
plasma	O
cells	O
as	O
per	O
iFISH	B-arm_description
,	O
i.e.	O
,	O
the	O
highest	O
percentage	O
of	O
a	O
chromosomal	O
aberration	O
,	O
was	O
95	O
%	O
(	O
SD	O
20	O
%	O
)	O
.	O

Samples	O
for	O
RNA	O
extraction	O
followed	O
by	O
quality	O
control	O
were	O
collected	O
over	O
2	O
weeks	O
each	O
and	O
then	O
subjected	O
to	O
gene	O
expression	O
profiling	O
by	O
DNA	O
-	O
microarrays	O
.	O
In	O
total	O
,	O
n	O
=	O
458	O
transcriptome	O
datasets	O
are	O
available	O
;	O
i.e.	O
,	O
81.9	O
%	O
of	O
patients	O
with	O
available	O
CD138-purified	O
plasma	O
cells	O
.	O
Of	O
these	O
,	O
two	O
patients	O
were	O
excluded	O
from	O
further	O
analysis	O
as	O
they	O
did	O
not	O
fulfill	O
the	O
inclusion	O
criteria	O
of	O
the	O
trial	O
.	O
Gene	O
expression	O
profiling	O
could	O
not	O
be	O
performed	O
in	O
53	O
cases	O
due	O
to	O
low	O
RNA	O
quality	O
(	O
9.5	O
%	O
)	O
and	O
further	O
48	O
cases	O
(	O
8.6	O
%	O
)	O
in	O
which	O
not	O
enough	O
RNA	O
was	O
available	O
(	O
Fig	O
.	O
1	O
)	O
.	O
Gene	O
expression	O
data	O
were	O
then	O
analyzed	O
and	O
reported	O
using	O
our	O
previously	O
published	O
GEP	B-arm_description
-	O
R	O
[	O
31	O
]	O
.	O

In	O
the	O
456	O
GEP	B-arm_description
-	O
R	O
from	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
,	O
we	O
exclude	O
an	O
interchange	O
of	O
samples	O
using	O
the	O
implemented	O
identity	O
control	O
.	O
Predictors	O
for	O
light	O
and	O
heavy	O
chain	O
type	O
(	O
overall	O
error	O
rate	O
2.2	O
%	O
and	O
1.6	O
%	O
,	O
respectively	O
)	O
as	O
well	O
as	O
the	O
sex	O
of	O
the	O
patient	O
(	O
5.5	O
%	O
overall	O
error	O
rate	O
,	O
in	O
agreement	O
with	O
frequent	O
loss	O
of	O
the	O
Ychromosome	O
[	O
51	O
]	O
;	O
being	O
"	O
female	O
"	O
can	O
be	O
predicted	O
without	O
error	O
)	O
showed	O
comparable	O
results	O
in	O
this	O
prospectively	O
analyzed	O
cohort	O
of	O
patients	O
if	O
compared	O
to	O
the	O
original	O
publication	O
(	O
retrospectively	O
on	O
the	O
validation	O
cohort	O
:	O
6	O
%	O
,	O
1	O
%	O
,	O
and	O
4	O
%	O
,	O
respectively	O
[	O
31	O
]	O
)	O
.	O
False	O
predictions	O
were	O
found	O
in	O
3/93	O
patients	O
with	O
IgA	O
myeloma	O
(	O
3.2	O
%	O
)	O
and	O
3/269	O
patients	O
with	O
IgG	O
(	O
1	O
%	O
)	O
as	O
well	O
as	O
4/308	O
patients	O
with	O
kappa	O
light	O
chains	O
(	O
1.3	O
%	O
)	O
and	O
6/148	O
patients	O
with	O
light	O
chains	O
type	O
lambda	O
(	O
4	O
%	O
;	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O
No	O
sample	O
failed	O
in	O
all	O
three	O
criteria	O
.	O

As	O
per	O
the	O
implemented	O
quality	O
control	O
with	O
a	O
total	O
of	O
7	O
quality	O
parameters	O
,	O
the	O
majority	O
of	O
patients	O
showed	O
no	O
abnormality	O
(	O
339	O
,	O
74.4	O
%	O
)	O
,	O
110	O
had	O
a	O
warning	O
in	O
one	O
minor	O
criterion	O
(	O
24.1	O
%	O
)	O
,	O
6	O
patients	O
in	O
2	O
(	O
1.3	O
%	O
)	O
,	O
and	O
1	O
patient	O
in	O
3	O
(	O
0.2	O
%	O
)	O
.	O
No	O
patient	O
fulfilled	O
one	O
of	O
the	O
major	O
exclusion	O
criteria	O
based	O
on	O
previously	O
performed	O
QC	O
analysis	O
.	O

Fifty	O
-	O
three	O
patients	O
were	O
predicted	O
using	O
the	O
GEP	B-arm_description
-	O
R	O
to	O
have	O
a	O
t	O
(	O
4;14	O
)	O
,	O
corresponding	O
to	O
11.6	O
%	O
of	O
the	O
total	O
cohort	O
with	O
available	O
GEP	B-arm_description
data	O
.	O
In	O
five	O
patients	O
,	O
iFISH	B-arm_description
and	O
GEP	B-arm_description
showed	O
discrepant	O
results	O
with	O
the	O
alteration	O
being	O
not	O
found	O
in	O
iFISH	B-arm_description
.	O
In	O
conservative	O
estimation	O
,	O
we	O
considered	O
the	O
PAM	O
-	O
based	O
predictor	O
to	O
have	O
an	O
overall	O
error	O
rate	O
of	O
1.1	O
%	O
.	O
Three	O
of	O
these	O
patients	O
had	O
a	O
clonal	O
IgHtranslocation	O
with	O
an	O
unknown	O
translocation	O
partner	O
,	O
one	O
patient	O
had	O
a	O
clonal	O
t	O
(	O
11;14	O
)	O
,	O
and	O
one	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
translocation	O
involving	O
the	O
IgHlocus	O
.	O
Predicted	O
t(4;14	O
)	O
status	O
delineated	O
significantly	O
different	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
40	B-arm_efficacy_results
vs.	I-arm_efficacy_results
26	I-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
P	I-arm_efficacy_results
=	I-arm_efficacy_results
0.008	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
median	O
OS	O
of	O
not	O
reached	O
(	O
NR	O
)	O
vs.	O
56	O
months	O
(	O
P	O
=	O
0.003	O
;	O
Additional	O
file	O
2	O
:	O
Figure	O
S1	O
)	O
.	O

Regarding	O
the	O
GEP70	B-arm_description
score	O
,	O
113	O
patients	O
were	O
attributed	O
as	O
being	O
high	O
risk	O
(	O
24.8	O
%	O
)	O
and	O
343	O
(	O
75.2	O
%	O
)	O
as	O
low	O
risk	O
which	O
transmitted	O
into	O
significantly	O
different	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
23	B-arm_efficacy_results
vs.	I-arm_efficacy_results
43	I-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
P	I-arm_efficacy_results
<	I-arm_efficacy_results
0.001	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
median	O
OS	O
of	O
41	O
months	O
vs.	O
NR	O
(	O
P	O
<	O
0.001	O
;	O
Additional	O
file	O
2	O
:	O
Figure	O
S1	O
)	O
.	O
The	O
same	O
holds	O
true	O
for	O
the	O
IFM15	O
score	O
with	O
106	O
patients	O
being	O
high	O
risk	O
(	O
23.2	O
%	O
)	O
and	O
350	O
patients	O
(	O
76.8	O
%	O
)	O
being	O
low	O
risk	O
transmitting	O
into	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
25	B-arm_efficacy_results
vs.	I-arm_efficacy_results
44	I-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
P	I-arm_efficacy_results
<	I-arm_efficacy_results
0.001	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
OS	O
of	O
57	O
months	O
vs.	O
NR	O
(	O
P	O
<	O
0.001	O
;	O
Additional	O
file	O
2	O
:	O
Figure	O
S1	O
)	O
.	O
Regarding	O
myeloma	O
cell	O
proliferation	O
,	O
36	O
(	O
7.9	O
%	O
)	O
,	O
191	O
(	O
41.9	O
%	O
)	O
,	O
and	O
229	O
(	O
50.2	O
%	O
)	O
patients	O
were	O
attributed	O
as	O
being	O
GPI	O
high	O
,	O
GPI	O
medium	O
,	O
and	O
GPI	O
low	O
,	O
respectively	O
with	O
significantly	O
different	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
18	B-arm_efficacy_results
vs.	I-arm_efficacy_results
33	I-arm_efficacy_results
vs.	I-arm_efficacy_results
49	I-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
P	I-arm_efficacy_results
<	I-arm_efficacy_results
0.001	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
median	O
OS	O
of	O
33	O
vs.	O
76	O
months	O
vs.	O
NR	O
(	O
P	O
<	O
0.001	O
;	O
Additional	O
file	O
2	O
:	O
Figure	O
S1	O
)	O
.	O

The	O
percentages	O
of	O
patients	O
identified	O
as	O
being	O
of	O
high	O
risk	O
by	O
conventional	O
prognostic	O
factors	O
,	O
gene	O
expressionbased	O
risk	O
scores	O
or	O
proliferation	O
(	O
GPI	O
)	O
,	O
as	O
well	O
as	O
metascores	O
and	O
the	O
overlap	O
of	O
the	O
respective	O
groups	O
of	O
patients	O
are	O
shown	O
in	O
Table	O
1	O
and	O
Fig	O
.	O
2	O
.	O

Expression	O
height	O
and	O
presence	O
/	O
absence	O
of	O
expression	O
were	O
assessed	O
for	O
(	O
i	O
)	O
examples	O
of	O
potential	O
"	O
target	O
genes	O
.	O
"	O
As	O
the	O
aim	O
of	O
our	O
manuscript	O
was	O
prospective	O
testing	O
of	O
the	O
GEP	B-arm_description
-	O
R	O
,	O
these	O
examples	O
include	O
AURKA	O
,	O
FGFR3	O
,	O
and	O
IGF1R	O
,	O
for	O
which	O
at	O
that	O
time	O
potential	O
clinical	O
grade	O
inhibitors	O
were	O
foreseen	O
,	O
(	O
ii	O
)	O
potential	O
targets	O
for	O
immunotherapy	O
,	O
i.e.	O
,	O
cancer	O
testis	O
antigens	O
like	O
CTAG1	O
,	O
MAGE1	O
,	O
and	O
HM1.24	O
,	O
and	O
(	O
iii	O
)	O
genes	O
frequently	O
Fig	O
.	O
1	O
Feasibility	O
of	O
plasma	O
cell	O
purification	O
,	O
iFISH	B-arm_description
,	O
and	O
gene	O
expression	O
profiling	O
within	O
the	O
GMMG	O
-	O
MM5	O
trial	O
.	O
Percentages	O
are	O
given	O
for	O
feasibility	O
of	O
plasma	O
cell	O
purification	O
(	O
ALL	O
)	O
as	O
well	O
as	O
performing	O
of	O
interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
iFISH	B-arm_description
)	O
and	O
gene	O
expression	O
profiling	O
(	O
GEP	B-arm_description
)	O
using	O
DNA	O
-	O
microarrays	O
.	O
For	O
the	O
latter	O
two	O
,	O
columns	O
refer	O
to	O
both	O
all	O
patients	O
and	O
those	O
for	O
which	O
purified	O
plasma	O
cells	O
were	O
available	O
.	O
BM(A	O
)	O
,	O
bone	O
marrow	O
(	O
aspiration	O
)	O
;	O
na	O
,	O
not	O
available	O
Table	O
1	O
Delineation	O
of	O
"	O
high	O
-	O
risk	O
"	O
patients	O
by	O
the	O
respective	O
variables	O
and	O
scores	O

The	O
percentages	O
of	O
patients	O
identified	O
as	O
being	O
of	O
high	O
risk	O
(	O
first	O
column	O
)	O
and	O
the	O
overlap	O
of	O
the	O
respective	O
groups	O
of	O
patients	O
are	O
shown	O
GPI	O
,	O
gene	O
expression	O
-	O
based	O
proliferation	O
index	O
;	O
(	O
r)ISS	O
,	O
(	O
revised	O
)	O
International	O
Staging	O
System	O
aberrantly	O
or	O
differentially	O
expressed	O
in	O
myeloma	O
.	O
In	O
our	O
cohort	O
of	O
456	O
patients	O
from	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
for	O
which	O
a	O
GEP	B-arm_description
-	O
R	O
is	O
available	O
,	O
197	O
were	O
found	O
to	O
express	O
AURKA	O
(	O
43.2	O
%	O
)	O
,	O
151	O
IGF1R	O
(	O
33.1	O
%	O
)	O
,	O
and	O
50	O
FGFR3	O
(	O
11	O
%	O
)	O
,	O
respectively	O
.	O
In	O
the	O
same	O
way	O
,	O
candidates	O
for	O
personalized	O
treatment	O
approaches	O
,	O
given	O
the	O
availability	O
of	O
respective	O
inhibitors	O
,	O
could	O
be	O
addressed	O
.	O

The	O
HM	O
metascore	O
had	O
already	O
been	O
validated	O
on	O
an	O
external	O
cohort	O
as	O
part	O
of	O
its	O
initial	O
set	O
up	O
[	O
31	O
]	O
.	O
In	O
prospective	O
testing	O
,	O
58	O
myeloma	O
patients	O
were	O
classified	O
as	O
being	O
low	O
risk	O
(	O
12.7	O
%	O
)	O
,	O
352	O
as	O
medium	O
risk	O
(	O
77.2	O
%	O
)	O
,	O
and	O
46	O
were	O
attributed	O
as	O
being	O
high	O
risk	O
(	O
10.1	O
%	O
)	O
.	O
This	O
transmitted	O
into	O
significant	O
different	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
NR	O
vs.	O
39	B-arm_efficacy_results
vs.	I-arm_efficacy_results
15	I-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
P	I-arm_efficacy_results
<	I-arm_efficacy_results
0.001	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
OS	O
of	O
NR	O
vs.	O
NR	O
vs.	O
41	O
months	O
(	O
P	O
<	O
0.001	O
)	O
.	O
At	O
5	O
years	O
,	O
survival	O
rate	O
was	O
98	O
%	O
vs.	O
68	O
%	O
vs.	O
25	O
%	O
and	O
57	O
(	O
98.2	O
%	O
)	O
vs.	O
253	O
(	O
71.8	O
%	O
)	O
vs.	O
15	O
(	O
32.6	O
%	O
)	O
patients	O
were	O
still	O
alive	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Applying	O
the	O
rISS	O
as	O
the	O
current	O
gold	O
standard	O
,	O
150	O
patients	O
were	O
classified	O
as	O
being	O
rISS	O
I	O
(	O
27.8	O
%	O
)	O
,	O
317	O
as	O
rISS	O
II	O
(	O
58.9	O
%	O
)	O
,	O
and	O
71	O
were	O
attributed	O
as	O
rISS	O
III	O
(	O
13.2	O
%	O
)	O
,	O
respectively	O
,	O
transmitting	O
into	O
significant	O
different	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
54	B-arm_efficacy_results
vs.	I-arm_efficacy_results
37	I-arm_efficacy_results
vs.	I-arm_efficacy_results
22	I-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
P	I-arm_efficacy_results
<	I-arm_efficacy_results
0.001	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
median	O
OS	O
of	O
NR	O
vs.	O
NR	O
vs.	O
41	O
months	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Five	O
-	O
year	O
PFS	O
and	O
OS	O
-	O
rates	O
for	O
rISS	O
I	O
/	O
II	O
/	O
III	O
were	O
44/30/18	O
%	O
and	O
86/65/40	O
%	O
,	O
respectively	O
(	O
Fig	O
.	O
3	O
)	O
.	O
Forest	O
plots	O
summarizing	O
the	O
prognostic	O
impact	O
of	O
individual	O
factors	O
and	O
metascores	O
(	O
i.e.	O
,	O
rISS	O
and	O
HM	O
metascore	O
)	O
can	O
be	O
found	O
in	O
Fig	O
.	O
4	O
.	O

An	O
integrated	O
Brier	O
score	O
was	O
calculated	O
to	O
assess	O
prediction	O
accuracy	O
.	O
The	O
overall	O
predictive	O
value	O
for	O
OS	O
from	O
0	O
to	O
73	O
months	O
is	O
best	O
for	O
the	O
HM	O
metascore	O
(	O
0.132	O
)	O
compared	O
to	O
rISS	O
(	O
0.137	O
)	O
or	O
other	O
GEP	O
-	O
based	O
scores	O
,	O
i.e.	O
,	O
the	O
GEP70-(0.139	O
)	O
,	O
IFM15	O
models	O
(	O
0.14	O
)	O
,	O
or	O
Reference	O
(	O
0.148	O
)	O
,	O
respectively	O
(	O
Fig	O
.	O
5	O
)	O
.	O
Differences	O
between	O
the	O
HM	O
metascore	O
and	O
the	O
other	O
models	O
were	O
,	O
however	O
,	O
not	O
statistically	O
significant	O
.	O
Likewise	O
,	O
differences	O
between	O
the	O
"	O
conventional	O
"	O
ISS	O
and	O
rISS	O
were	O
not	O
significantly	O
different	O
.	O

Despite	O
iFISH	B-arm_description
,	O
GEP	B-arm_description
and	O
RNA	O
-	O
sequencing	O
have	O
been	O
used	O
in	O
academic	O
setting	O
or	O
using	O
commercial	O
providers	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
data	O
is	O
available	O
regarding	O
a	O
prospective	O
molecular	O
analysis	O
and	O
reporting	O
in	O
clinical	O
routine	O
in	O
a	O
way	O
that	O
this	O
could	O
be	O
used	O
for	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
,	O
e.g.	O
,	O
during	O
the	O
first	O
cycle	O
of	O
induction	O
chemotherapy	O
.	O
This	O
is	O
a	O
different	O
setting	O
from	O
being	O
able	O
to	O
run	O
advanced	O
molecular	O
diagnostics	O
in	O
a	O
prospective	O
trial	O
in	O
a	O
subpopulation	O
of	O
patients	O
which	O
has	O
frequently	O
been	O
shown	O
by	O
others	O
and	O
us	O
[	O
8,17,[23][24][25][26][27][28	O
]	O
.	O

Alongside	O
the	O
principle	O
possibility	O
of	O
running	O
advanced	O
molecular	O
profiling	O
and	O
depiction	O
of	O
potential	O
targets	O
for	O
individualized	O
treatment	O
,	O
assessment	O
of	O
risk	O
was	O
the	O
third	O
main	O
objective	O
of	O
our	O
study	O
.	O
Here	O
,	O
many	O
prognostic	O
factors	O
have	O
been	O
described	O
with	O
the	O
ongoing	O
discussion	O
of	O
which	O
to	O
include	O
[	O
19,20	O
]	O
.	O
This	O
leaves	O
the	O
treating	O
physician	O
with	O
a	O
plethora	O
of	O
information	O
that	O
is	O
difficult	O
to	O
consolidate	O
intending	O
counseling	O
patients	O
and	O
drawing	O
a	O
clinical	O
conclusion	O
.	O
Metascoring	O
appears	O
as	O
an	O
appropriate	O
strategy	O
[	O
18,31,60,61	O
]	O
to	O
overcome	O
this	O
,	O
and	O
we	O
show	O
that	O
this	O
is	O
likewise	O
possible	O
in	O
a	O
randomized	O
clinical	O
trial	O
setting	O
.	O
Regarding	O
the	O
molecular	O
techniques	O
used	O
in	O
the	O
metascore	O
,	O
i.e.	O
,	O
iFISH	B-arm_description
and	O
GEP	B-arm_description
,	O
we	O
choose	O
to	O
include	O
both	O
due	O
to	O
in	O
part	O
non	O
-	O
overlapping	O
prognostic	O
information	O
,	O
e.g.	O
,	O
it	O
is	O
not	O
possible	O
to	O
predict	O
del17p13	O
at	O
a	O
high	O
-	O
enough	O
accuracy	O
by	O
GEP	B-arm_description
[	O
62	O
]	O
.	O
The	O
actual	O
(	O
good	O
)	O
prediction	O
result	O
of	O
our	O
metascore	O
per	O
se	O
is	O
thereby	O
not	O
the	O
main	O
focus	O
of	O
our	O
analysis	O
.	O
Nonetheless	O
,	O
even	O
with	O
this	O
"	O
2010	O
choice	O
"	O
regarding	O
risk	O
factors	O
and	O
target	O
genes	O
,	O
metascoring	O
including	O
GEPbased	B-arm_description
risk	O
assessment	O
is	O
superior	O
in	O
numbers	O
to	O
rISS	O
,	O
although	O
not	O
statistically	O
so	O
.	O
The	O
same	O
however	O
holds	O
true	O
for	O
a	O
comparison	O
of	O
rISS	O
to	O
ISS	O
even	O
on	O
our	O
comparably	O
large	O
cohort	O
of	O
patients	O
.	O

In	O
conclusion	O
,	O
using	O
an	O
elaborated	O
sampling	O
,	O
experimental	O
and	O
analysis	O
strategy	O
as	O
reported	O
here	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
it	O
is	O
possible	O
to	O
prospectively	O
perform	O
and	O
report	O
molecular	O
analyses	O
in	O
a	O
randomized	O
phase	O
III	O
multicenter	O
trial	O
in	O
over	O
90	O
%	O
(	O
iFISH	B-arm_description
)	O
and	O
80	O
%	O
(	O
GEP	B-arm_description
)	O
of	O
patients	O
,	O
respectively	O
,	O
within	O
the	O
first	O
cycle	O
of	O
induction	O
chemotherapy	O
.	O
Therefore	O
,	O
we	O
validate	O
that	O
a	O
trial	O
strategy	O
using	O
either	O
of	O
the	O
methods	O
is	O
possible	O
,	O
including	O
reporting	O
of	O
potentially	O
actionable	O
targets	O
.	O
Risk	O
assessment	O
using	O
our	O
HM	O
metascore	O
allows	O
to	O
stratify	O
patients	O
with	O
excellent	O
/	O
intermediate	O
/	O
adverse	O
PFS	B-arm_efficacy_metric
and	O
OS	O
with	O
survival	O
rates	O
of	O
98	B-arm_efficacy_results
%	I-arm_efficacy_results
vs.	I-arm_efficacy_results
68	I-arm_efficacy_results
%	I-arm_efficacy_results
vs.	I-arm_efficacy_results
25	I-arm_efficacy_results
%	I-arm_efficacy_results
,	O
respectively	O
,	O
after	O
5	O
years	O
.	O
In	O
comparison	O
to	O
the	O
rates	O
by	O
rISS	O
of	O
86	O
%	O
vs.	O
65	O
%	O
vs.	O
40	O
%	O
,	O
respectively	O
,	O
both	O
groups	O
with	O
better	O
as	O
well	O
as	O
more	O
adverse	O
survival	O
are	O
delineated	O
by	O
the	O
HM	O
metascore	O
.	O